Do Temporal Lobe Tangles and Cortical Plaques Together Bring on Alzheimer’s?
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
Unbiased Screen Fingers TREM2 Ligands That Promote Aβ Uptake
At Keystone, researchers also linked the receptor to microglial homeostasis and migration, and resolved lingering questions about TREM2’s role in plaque clearance.
Bu, Kivipelto, Cirrito, and Slutsky Win MetLife Awards
Four researchers received awards totaling $350,000 for their contributions to Alzheimer’s research.
Tipping the Balance Toward Four-Repeat Tau Exacerbates Toxicity in Mice
Antisense oligonucleotides can flip expression of tau from the three-repeat to the four-repeat form. These ASOs triggered tau aggregation and behavioral problems.
Alzheimer's Association International Conference 2016
In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period. Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials Access: How to Bring People in ‘From the
Genetic Studies Uncover Four New ALS Genes
Scientists pool samples and creatively mine the genomes of thousands of patients to find coding and non-coding variants that associate with the disease.
Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials
This past year, the Global Alzheimer’s Platform and the European Prevention of Alzheimer’s Dementia have moved quickly, and jointly, to pave the way toward more, faster, cheaper trials. Will they be better, too?
Access: How to Bring People in ‘From the Wild’?
Alarmed by crushing screen failure rates of the first prodromal Alzheimer’s trials, EPAD and GAP are chasing new ways to reach people who don’t know they really should be in a secondary prevention trial.
Playing Where the Puck Is Going to Be: Trial Sites Skate Toward GAP Net, EPAD TDCs
Clinical trial centers are preparing to position themselves as standing networks, with standardized paperwork, clinical rater systems, and a central IRB, for trials anticipated to start late next year.
PreDIVA Trial Falls Short
Dementia incidence in intervention group was no different from control, though targeting hypertension may protect, researchers say.
At Age 8, DIAN Is Churning Out Data and Growing into a Movement
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
DIAN Longitudinal Data Say Cognition Goes Earlier Than Previously Thought
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
Brain Imaging in DIAN: Atrophy Rates—Check. Tau PET—Not Yet.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Monogenetic and Sporadic Alzheimer’s Disease: Same or Different?
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
DIAN’s Tightrope Act: Sharing Data While Protecting Your Wish Not to Know
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.
Current Filters
No filters selected